Veronica Miller, PhD

Veronica Miller is a Research Professor.

• Phone: (202) 530-2311
• Fax: (202) 530-3923
• Email: vmiller@gwu.edu

Professor Miller's intellectual journey has taken her from JW Goethe University in Frankfurt, Germany, where she directed an interdisciplinary HIV clinical research program, to GW, where she oversees a group that helps to shape the HIV research agenda for the future. "Early on, we recognized the need to learn from each patient and set of patients participating in clinical studies," she says, which led her to help establish the Frankfurt HIV cohort. Studies of that population have generated important data about treatment effectiveness and viral drug resistance, and influenced regulatory policy in Europe and North America. With knowledge evolving rapidly, Professor Miller also co-founded and chaired the EuroGuidelines Group in 1999 to create uniform standard-of-care guidelines across the continent.

In becoming Director of the Forum for Collaborative HIV Research, which works to advance clinical research and translate results into patient care, Professor Miller has emphasized the importance of involving all stakeholders in driving the field of HIV treatment forward. Under her leadership, the Forum has expanded to include a focus on global HIV issues. In addition to her academic appointment in the Department of Prevention and Community Health, Professor Miller holds secondary appointments in the Departments of Epidemiology & Biostatistics and of Health Policy.

Education

Bachelor of Science (Microbiology), University of Manitoba, 1976
Doctor of Philosophy (Immunology), University of Manitoba, 1985

Teaching

PubH 209-Issues in HIV Treatment, Department of Epidemiology and Biostatistics

Research

Professor Miller has published extensively on HIV treatment strategies, especially on the immunological and virological impact of antiretroviral drug protocols. A key area of interest is viral drug resistance and the characterization of treatment failure.

Community Service

Professor Miller serves on numerous industry and government advisory boards, including the FDA Antiviral Advisory Committee. She participated in the NIH Office of AIDS Research Planning Workshop for HIV/AIDS Research and on the NIH's Special Emphasis Panel focused on enrolling women and minority populations in clinical trials of microbicides and HIV vaccines.

Departments

• Epidemiology and Biostatistics
• Health Policy
• Prevention and Community Health

Institutes & Centers

• Forum for Collaborative HIV Research
• Prevention Research Center

Research Activities

• Clinical Relevance of Drug Resistance
• Forum for Collaborative HIV Research
• Point-of-Care Monitoring for HIV: Moving the Field Forward
• Surveillance of HIV-1 Drug Resistance in North America

Publications

• Antiretroviral therapies for treatment-experienced patients: current status and research challenges.
  Struble K, Murray J, Cheng B, Gegeny T, Miller V, Gulick R. Antiretroviral therapies for treatment-experienced patients: current status and research challenges. AIDS 2005;19:747-56.
• Sifting through the maze of viral and host diversity and clinical progression.
Miller V. Sifting through the maze of viral and host diversity and clinical progression. Int J Epidemiol 2005;34:584-585. Available from: URL: http://ije.oxfordjournals.org/cgi/reprint/dyi090?ijkey=C1MKtSzl3I18sbh&keytype=ref
• Integration of Buprenorphine into HIV primary care.
  Integration of Buprenorphine into HIV primary care. Report based on the Forum for Collaborative HIV Research Workshop; 2005 Mar. Available from: URL: http://www.hivforum.org
• Progress in spite of protest?
  Miller V. Bangkok 2004: Progress in spite of protest? The Physicians’ Research Network (PRN) Notebook 2004;9:33-6.
• Clinically validated genotype analysis: guiding principles and statistical concerns.
  Brun-Vezinet F, Costagliola D, Ait Khaled M, Calvez V, Clavel F, Clotet B, et al. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther 2004;9:465-78.
• HIV-1 co-infection and superinfection: generation of viral diversity.
  Miller V. HIV-1 co-infection and superinfection: generation of viral diversity. Guest editorial. HIV/AIDS Current Trends 2004;10:1.
• Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs.
  Reddy YS, Kashuba A, Gerber J, Miller V. Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs. AIDS Res Hum Retroviruses 2003;19:167-76.
• For the roundtable participants. Roundtable discussion report: protein binding in antiretroviral therapies.
  Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, Miller V. For the roundtable participants. Roundtable discussion report: protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003;19:825-35.
• Monitoring of long-term toxicities of HIV treatments: An international perspective.
  Bisson G, Gross R, Evans S, Graham D, Lundgren J, Murray J, et al. Monitoring of long-term toxicities of HIV treatments: An international perspective. AIDS 2003;17:2407-17.
• Cardiovascular risk in HIV infection and treatment.
  Cardiovascular risk in HIV infection and treatment. Report based on the Forum for Collaborative HIV Research Expert Roundtable Discussion; 2003 May. Available from: URL: http://www.hivforum.org/publications/CVD%20RISK%20AUG%2019%20W%20LOGO.pdf
• To stop or not to stop: that is the question, but what is the answer?
  Hogg RS, Havlir D, Miller V, Montaner JSG. To stop or not to stop: that is the question, but what is the answer? AIDS 2002;16:1-3.
• For the EuroSIDA Study Group. Association of viral load, CD4 cell count and treatment with clinical progression in HIV patients with very low CD4 cell counts: the EuroSIDA study.
  Miller V, Mocroft A, Clotet B, Ledergerber B, Kirk O, D’Arminio Monforte A, Lundgren J. For the EuroSIDA Study Group. Association of viral load, CD4 cell count and treatment with clinical progression in HIV patients with very low CD4 cell counts: the EuroSIDA study. J Infect Dis 2002;186:189-97.
• The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response.
  Miller V, Stark T, Leoliger AE, Lange JMA. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med 2002;3:135-45.
• Quality of HIV care – closing the gap.
  Quality of HIV care – closing the gap. Report on the findings from the Forum for Collaborative HIV Research Quality of HIV Care Project; 2002 Dec. Available from: URL: http://www.hivforum.org/publications/
  Quality%20of%20HIV%20Care%20-%20Closing%20the%20Gap%20-complete.pdf
• Sex and gender issues in HIV disease.
  Sex and gender issues in HIV disease. Report based on the Forum for Collaborative HIV Research Workshop; 2002 Nov. Available from: URL: http://www.hivforum.org/publications/S&G%20Final.pdf
• Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing in treatment management: Recommendations for the European setting.
  EuroGuidelines Group. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing in treatment management: Recommendations for the European setting. AIDS 2001;15(3):309-20.
• Structured treatment interruptions (STI) in antiretroviral management of HIV-1.
  Miller V. Structured treatment interruptions (STI) in antiretroviral management of HIV-1. Curr Opin Infect Dis 2001;14:29-37.
• Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up.
  Vandamme A-M, Houyez F, Bànhegyi D, Clotet B, De Schrijver G, De Smet KAL, et al. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir Ther 2001;6:21-40.
• World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.
  Harrigan PR, Montaner JSG, Wegner SA, Verbiest W, Miller V, Wood R, Larder BA. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001;15(13):1671-7.
• Initiation of antiretroviral therapy: HIV-1 viral load response according to the baseline CD4 lymphocyte count and viral load.
  Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. For the Swiss HIV cohort study, the Frankfurt HIV clinic cohort, and the EuroSIDA study group. Initiation of antiretroviral therapy: HIV-1 viral load response according to the baseline CD4 lymphocyte count and viral load. JAMA 2001;286:2560-7.
• Mutational patterns in the HIV genome and cross resistance following nucleoside and nucleotide analogue drug exposure.
  Miller V, Larder B. Mutational patterns in the HIV genome and cross resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther 2001;6(Suppl 3):25-44.
• HIV-1 reverse transcriptase (RT) genotype and viral sensitivity to RT inhibitors during abacavir monotherapy and after switch to zidovudine, lamivudine and abacavir HAART
  Miller V, Ait-Khaled A, Stone C, Griffin P, Mesogiti D, Cutrell A, et al. HIV-1 reverse transcriptase (RT) genotype and viral sensitivity to RT inhibitors during abacavir monotherapy and after switch to zidovudine, lamivudine and abacavir HAART. AIDS 2000;14 (2):163-71.
• Resistance profiles in patients with viral rebound on potent antiretroviral therapy.
  Cozzi Lepri A, Sabin C, Staszewski S, Hertogs K, Müller A, Rabenau H, et al. Resistance profiles in patients with viral rebound on potent antiretroviral therapy. J Infect Dis 2000;181:1143-7.
• HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort.
  Miller V, Cozzi-Lepri A, Hertogs K, Gute P, Larder B, Bloor S, et al. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antiviral Ther 2000;5:49-55.
• The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.
  DeGrutolla V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Kahled M, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-8.
• The impact of PI-containing HAART on progression of HIV disease and its relationship to CD4 and viral load.
  Miller V, Sabin C, Phillips AN, Rottmann C, Rabenau H, Weidmann E, et al. The impact of PI-containing HAART on progression of HIV disease and its relationship to CD4 and viral load. AIDS 2000;14:2129-36.
• Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.
  Miller V, Sabin C, Hertogs K, Larder B, Bloor S, Martinez-Picado J, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000;14(18):2857-67.
• European guidelines on resistance testing: why are they needed?
  Miller V. European guidelines on resistance testing: why are they needed? Guest Editorial for HIV Med 2000;1:129-31.
• The prevalence of drug-resistant HIV as revealed by cohort studies.
  Miller V. The prevalence of drug-resistant HIV as revealed by cohort studies. Guest editorial. HIV/AIDS Current Trends 2000;6 (4):1-3.
• Relations among CD4 count nadir, antiretroviral therapy and HIV-1disease progression: results from the EuroSIDA study.
  Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, et al. Relations among CD4 count nadir, antiretroviral therapy and HIV-1disease progression: results from the EuroSIDA study. Ann Intern Med 1999;130:570-7.